Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular...

8

Transcript of Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular...

Page 1: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 2: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 3: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 4: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 5: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 6: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 7: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal
Page 8: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal